You are here: Industry Insights > NDA

News List

Blueprint Medicines Announces FDA Acceptance of NDA for Avapritinib americanpharmaceuticalreview
August 09, 2019
Blueprint Medicines announced the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for avapritinib for the treatment of adult patients with ...
FDA Accepts Correvio's Resubmitted NDA for Brinavess americanpharmaceuticalreview
July 29, 2019
Correvio Pharma announced the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for Brinavess™ (vernakalant hydrochloride, IV), an antiarrhythmic drug for ...
Epizyme Announces NDA Acceptance, Priority Review for Tazemetostat americanpharmaceuticalreview
July 26, 2019
Epizyme announced the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for accelerated approval of tazemetostat, its lead investigational agent.
Vertex Submits NDA for Triple Combination of VX-445, Tezacaftor, Ivacaftor in Cystic Fibrosis americanpharmaceuticalreview
July 23, 2019
Vertex Pharmaceuticals announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen.
FDA Accepts RedHill Biopharma’s NDA for Talicia contractpharma
July 17, 2019
Commercial launch of H. pylori treatment is planned shortly following potential FDA approval.
Neurocrine Biosciences Announces NDA Acceptance of Parkinson's Treatment americanpharmaceuticalreview
July 12, 2019
Neurocrine Biosciences announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for opicapone, a novel, once-daily, oral, selective catechol-O-methyltransferase (COMT) inhibitor as ...
Acacia Pharma Plans to Resubmit the Barhemsys NDA in Q3 2019 drugs
July 11, 2019
Acacia Pharma Plans to Resubmit the Barhemsys NDA in Q3 2019.
NMPA accepts NDA for biosimilar product candidate of Rituximab biospectrumasia
June 28, 2019
IBI301 is a recombinant human-mouse chimeric anti-cell surface protein (anti-CD20) monoclonal antibody for injection co-developed by Lilly and Innovent for the treatment of non-Hodgkin's lymphoma (NHL) and other diseases.
Zosano Pharma Completes Site Qualification Batches for NDA contractpharma
June 24, 2019
Tech transfer of manufacturing process to CMO signals commencement of commercial readiness activities.
Blueprint Medicines Submits NDA for Avapritinib americanpharmaceuticalreview
June 20, 2019
Blueprint Medicines has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for avapritinib for the treatment of adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumors (GIST) ...

Previous page 1 2 3 4 5 6 7 8 Next page